ALLMedicine™ Amyotrophic Lateral Sclerosis Center
Research & Reviews 7,385 results
https://clinicaltrials.gov/ct2/show/NCT02988297
Mar 29th, 2023 - The purpose of this study is to determine whether nebulized RNS60 is effective in the treatment of amyotrophic lateral sclerosis (ALS).
https://doi.org/10.1111/cns.14193
CNS Neuroscience & Therapeutics; Liu P, Tang Y et. al.
Mar 28th, 2023 - To study the brain metabolic signature in Chinese amyotrophic lateral sclerosis (ALS) patients and compare the difference in brain metabolic patterns between ALS with and without genetic variants. We included 146 patients with ALS and 128 healthy ...
https://clinicaltrials.gov/ct2/show/NCT04768972
Mar 28th, 2023 - This is a multi-center, two-part study of ION363 in up to 77 participants. Part 1 will consist of participants that will be randomized in a 2:1 ratio to receive a multi-dose regimen of ION363 or placebo for a period of 61 weeks, followed by Part 2...
https://clinicaltrials.gov/ct2/show/NCT05039099
Mar 27th, 2023 - The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
https://doi.org/10.1016/j.neuron.2023.02.028
Neuron Piol D, Robberechts T et. al.
Mar 25th, 2023 - Key early features of amyotrophic lateral sclerosis (ALS) are denervation of neuromuscular junctions and axonal degeneration. Motor neuron homeostasis relies on local translation through controlled regulation of axonal mRNA localization, transport...
Guidelines 4 results
https://doi.org/10.1016/j.chest.2023.03.011
Chest Khan A, Frazer-Green L et. al.
Mar 16th, 2023 - Respiratory failure is a significant concern in neuromuscular diseases (NMD). This CHEST guideline examines the literature on the respiratory management of patients with NMD to provide evidence-based recommendations. An expert panel conducted a sy...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.
Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.
Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.
Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...
Drugs 18 results see all →
Clinicaltrials.gov 556 results
https://clinicaltrials.gov/ct2/show/NCT02988297
Mar 29th, 2023 - The purpose of this study is to determine whether nebulized RNS60 is effective in the treatment of amyotrophic lateral sclerosis (ALS).
https://clinicaltrials.gov/ct2/show/NCT04768972
Mar 28th, 2023 - This is a multi-center, two-part study of ION363 in up to 77 participants. Part 1 will consist of participants that will be randomized in a 2:1 ratio to receive a multi-dose regimen of ION363 or placebo for a period of 61 weeks, followed by Part 2...
https://clinicaltrials.gov/ct2/show/NCT05039099
Mar 27th, 2023 - The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
https://clinicaltrials.gov/ct2/show/NCT04569435
Mar 24th, 2023 - In this Phase 2a, multi-center, open label, proof-of-biology study, ANX005 will be administered to participants with ALS. The study consists of approximately 22 weeks of treatment and approximately 14 weeks of follow-up. All participants will be c...
https://clinicaltrials.gov/ct2/show/NCT04559009
Mar 24th, 2023 - The purpose of this registry is to assess the incidence and prevalence of COVID-19 in ALS patients, the effect of COVID-19 on ALS disease trajectory, and the impact, if any, of edaravone, riluzole and other concomitant medication used in ALS like ...
News 492 results
https://www.medpagetoday.com/neurology/generalneurology/103757
Mar 28th, 2023 - An umbrella review of meta-analyses showed a positive overall effect of exercise on cognition, but the underlying studies had substantial limitations. (Nature Human Behaviour) SARS-CoV-2 infection during pregnancy was associated with a higher risk...
https://www.medpagetoday.com/neurology/generalneurology/103672
Mar 23rd, 2023 - A panel of FDA advisors voted unanimously that plasma neurofilament light chain (NfL), a biomarker of neurodegeneration, is a reasonable surrogate endpoint in amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene (SOD1-AL...
https://www.medpagetoday.com/neurology/generalneurology/103620
Mar 20th, 2023 - Tofersen, an investigational antisense drug developed to treat amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene (SOD1-ALS), may have clinical benefit, FDA reviewers indicated in briefing documents ahead of an advisor...
https://www.medpagetoday.com/neurology/dementia/103563
Mar 16th, 2023 - Men who played elite soccer were more likely to develop neurodegenerative diseases -- notably, dementia -- as they aged, a study in Sweden showed. The risk of neurodegenerative disease was 46% higher among soccer players who played in the Swedish ...
https://www.medpagetoday.com/pulmonology/generalpulmonary/103571
Mar 16th, 2023 - Physicians should incorporate respiratory health care in early treatment plans for patients with neuromuscular diseases (NMD), according to new clinical guidelines from the American College of Chest Physicians (CHEST). Non-invasive ventilation, su...